Introduction: The Promise and Complexity of PRP in Sports Medicine

Platelet-rich plasma (PRP) therapy has generated intense interest in sports medicine over the past decade as athletes and clinicians seek regenerative alternatives to surgery and prolonged rest. For tendon injuries—whether a runner’s chronic Achilles tendinopathy, a basketball player’s patellar tendinopathy, or a tennis athlete’s lateral epicondylitis—PRP offers a biologically driven strategy that leverages the patient’s own healing factors. The procedure involves drawing whole blood, centrifuging it to concentrate platelets and their associated growth factors, and injecting the resulting plasma into the damaged tendon. Enthusiasts highlight the potential for accelerated healing and return to sport without the risks of surgery, while skeptics point to conflicting clinical trial results and the absence of standardized protocols. This review provides an authoritative, evidence-based examination of PRP for tendon injuries in athletes, covering the biological rationale, clinical effectiveness across common injury sites, practical limitations, and future directions to help clinicians and athletes make informed decisions.

Understanding Platelet-Rich Plasma: Preparation and Biological Rationale

PRP is derived from autologous whole blood using a centrifugation process that separates cellular components by density. The resulting plasma typically contains a platelet concentration three to five times greater than baseline levels. Platelets store alpha granules rich in growth factors—including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). When injected into an injured tendon, these factors create a local microenvironment that recruits stem cells, stimulates tenocyte proliferation, promotes angiogenesis, and regulates collagen synthesis and matrix remodeling. The biological rationale is compelling: tendons have limited vascularity and heal slowly, so a concentrated dose of endogenous growth factors may overcome this deficit.

Importantly, PRP preparations vary substantially between clinics and studies. Key variables include centrifugation speed and duration (single vs. double spin), the use of anticoagulants (e.g., citrate), and—most critically—leukocyte content. Leukocyte-rich PRP (L-PRP) contains white blood cells that can release pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), potentially contributing to an initial inflammatory response. Leukocyte-poor PRP (P-PRP) is considered more anti-inflammatory by removing most leukocytes. A 2019 systematic review in the American Journal of Sports Medicine indicated that L-PRP may be more effective for chronic tendinopathy, while P-PRP is associated with fewer post-injection reactions. Additionally, platelet activation methods—using calcium chloride or thrombin—further influence growth factor release. Understanding these variations is essential when interpreting clinical outcomes and when designing treatment protocols.

Mechanism of Action in Tendon Healing

Tendons are dense connective tissues composed primarily of type I collagen organized in hierarchical fibrils. Their low vascularity and cellular density make them recalcitrant to healing. After acute injury or in chronic overuse, the natural repair process often results in disorganized scar tissue that is biomechanically inferior. PRP targets this deficiency by delivering supraphysiologic concentrations of growth factors directly to the lesion. In vitro studies demonstrate that PRP increases tenocyte and myofibroblast proliferation, upregulates collagen type I and III expression, and enhances the secretion of matrix metalloproteinases (MMPs) necessary for remodeling.

Beyond direct cellular effects, PRP modulates the inflammatory milieu. Tendinopathy is now understood to involve both degenerative and inflammatory components, with dysregulated cytokine signaling contributing to persistent pain. PRP can shift the balance from a chronic pro-inflammatory state (characterized by high levels of IL-1β and TNF-α) toward a pro-regenerative environment, promoting resolution of inflammation and tissue repair. Animal models have shown improved tendon biomechanical properties—such as ultimate tensile strength, stiffness, and energy to failure—after PRP injection. However, translation to human athletes remains inconsistent due to differences in injury chronicity, PRP formulation, concomitant treatments, and rehabilitation compliance. A critical point emphasized by recent consensus statements is that PRP is not a stand-alone intervention; it primes the tissue for repair, but functional loading through structured rehabilitation is essential to direct and strengthen that repair.

Clinical Evidence by Tendon Injury Subtype

The evidence base for PRP varies by anatomical location and injury nature. Some areas show consistently positive results, while others remain controversial. Below we examine the most studied applications in athletes.

Achilles Tendinopathy

Achilles tendinopathy is prevalent among runners, jumpers, and court-sport athletes. Multiple randomized controlled trials (RCTs) have compared PRP to placebo or eccentric exercise. A 2014 meta-analysis of 8 RCTs in the Journal of Bone and Joint Surgery reported that PRP provided significant pain reduction and improved functional scores up to 12 months in chronic cases (duration >6 months). More recent prospective studies reinforce these findings, with athletes returning to sport earlier when PRP was combined with progressive loading. However, a landmark placebo-controlled RCT in the New England Journal of Medicine (2010) found no superiority of PRP over saline injection in chronic mid-portion Achilles tendinopathy at 6 to 12 months, sparking debate. Differences in preparation methods (leukocyte-rich vs. poor) and injection technique likely explain the discrepancy. Current expert consensus suggests that leukocyte-rich PRP (L-PRP) is more beneficial for chronic Achilles tendinopathy due to its pro-repair inflammatory initiation, while leukocyte-poor formulations are preferred for acute injuries to avoid excessive inflammation. Ultrasound guidance is recommended to ensure peritendinous placement rather than intratendinous injection, which can increase pain.

Patellar Tendinopathy (Jumper’s Knee)

Patellar tendinopathy affects athletes in explosive sports like basketball, volleyball, and track. Evidence is moderately favorable. A 2013 RCT in the American Journal of Sports Medicine randomized 46 athletes to PRP or dry needling and found significantly greater improvements in pain and function in the PRP group at 6 and 12 months. A 2020 systematic review confirmed that PRP was superior to control treatments (saline, dry needling) in the short term (3–6 months), but not clearly superior to shockwave therapy or eccentric exercise alone. Many clinicians now consider PRP a second-line therapy after a failed 3–6 month course of physical therapy. The patellar tendon is superficial and bears high loads; careful ultrasound-guided technique is critical to avoid intratendinous injection, which can exacerbate pain. Post-injection rehabilitation should progress from isometric to eccentric loading over several weeks.

Rotator Cuff Tendinopathy

The rotator cuff is more complex due to the frequent coexistence of tendinopathy and partial-thickness tears. PRP is used both as a standalone treatment and as an adjunct to surgical repair. For non-operative management of chronic rotator cuff tendinopathy, a 2019 systematic review of 12 RCTs reported moderate evidence that PRP reduces pain and improves function compared to corticosteroid injections or placebo, especially in patients with partial-thickness tears. However, effects were modest when compared to structured exercise programs. In the surgical setting, PRP applied to the repair site has shown inconsistent results. Some studies report improved healing rates and reduced retear rates, particularly with leukocyte-rich PRP for small-to-medium tears (retear risk reduction of about 25%), while others find no significant benefit for large or massive tears. Athletes should discuss these nuances with a sports medicine shoulder specialist and consider PRP as part of a comprehensive plan that includes physical therapy and activity modification.

Lateral Epicondylitis (Tennis Elbow)

Tennis elbow is one of the most robust areas of PRP research. Multiple high-quality RCTs, including a seminal 2013 study in JAMA, demonstrated that PRP injections lead to superior pain reduction and functional improvements compared to corticosteroid injections at 6 months and beyond. The JAMA trial reported a 25% greater reduction in pain scores with PRP at 6 months. A 2022 Cochrane review concluded that PRP likely reduces pain and improves function in the medium term (3–12 months), though short-term effects (<6 weeks) are not significant. For athletes whose lateral epicondylitis persists beyond 3 months despite bracing and physical therapy, PRP is now considered a reasonable second-line treatment. Typically, one to three injections are performed 4–6 weeks apart. The mechanism may involve stimulating a regenerative response that addresses the underlying tendinopathy rather than simply suppressing pain as corticosteroids do.

Comparing PRP to Alternative Therapies

In clinical decision-making, PRP is often compared to corticosteroid injections, shockwave therapy, and physical therapy. Corticosteroid injections provide rapid, short-term pain relief but are associated with high recurrence rates and potential tendon weakening with repeated use. PRP offers a more disease-modifying approach—promoting repair rather than masking inflammation. Extracorporeal shockwave therapy (ESWT) is a non-invasive option with moderate efficacy for recalcitrant tendinopathies, particularly of the plantar fascia and patellar tendon. Direct comparisons between ESWT and PRP are limited, but a 2018 meta-analysis suggested PRP may be superior for lateral epicondylitis in the long term, while ESWT is comparable for Achilles and patellar tendinopathy. Physical therapy—especially eccentric exercise—remains the foundational treatment for tendinopathy, and PRP should be considered an adjunct, not a replacement. The best candidate for PRP is an athlete who has failed an adequate trial of conservative therapy (typically 3–6 months) and who is motivated to follow a structured post-injection rehabilitation program.

Factors Influencing PRP Outcomes

Not all athletes respond equally to PRP. Several evidence-based factors influence success. Injury chronicity is a strong predictor: chronic tendinopathies (>6 months) consistently show better response than acute injuries, likely because chronic cases have a more dysregulated healing process that PRP can modulate. PRP preparation and leukocyte content matter—L-PRP appears beneficial for chronic conditions, while P-PRP is preferred for acute or post-operative settings to avoid excessive inflammation. Injection technique is critical; ultrasound guidance improves accuracy and reduces complications such as intratendinous injection, which can increase pain. Patient age and activity level affect healing potential; younger athletes with higher training loads tend to respond better. Compliance with rehabilitation is perhaps the most modifiable factor. PRP primes the tissue for repair, but loading through prescribed exercise is necessary to direct and strengthen that repair. Without proper rehab, benefits are greatly diminished. Clinicians should set clear expectations: PRP is part of a comprehensive plan, not a quick fix, and may require 2–3 injections over 12–16 weeks.

Limitations, Risks, and Practical Considerations

PRP is generally safe because it is autologous, eliminating the risk of immunogenic reactions or disease transmission. Common side effects include temporary pain, swelling, and stiffness at the injection site, typically resolving within 48 hours. However, several limitations deserve attention. First, the heterogeneity of PRP preparations makes it difficult to replicate studies and to know which formulation to use for which injury. Second, many published studies have small sample sizes, variable control groups, and short follow-up, limiting the strength of conclusions. Third, PRP is expensive—costing $500 to $1,500 per injection in the United States—and is often not covered by insurance, creating a financial barrier for athletes. Fourth, repeated injections (often 2–3) may be required, doubling cost and time commitment. Fifth, there is a theoretical risk of promoting fibrosis or calcification if growth factor signaling is dysregulated, though clinical evidence for this is minimal. Researchers and organizations like the American Academy of Orthopaedic Surgeons continue to work toward evidence-based clinical practice guidelines for PRP use.

PRP Protocols and Injection Techniques

Standardization of PRP protocols is needed to improve reproducibility. Currently, most sports medicine specialists follow these general steps: after obtaining informed consent, whole blood (30–60 mL) is drawn and processed using a commercial PRP system or a laboratory centrifuge. The resulting PRP (3–6 mL) is activated with calcium chloride or thrombin immediately before injection. For most tendons, the injection is performed under ultrasound guidance to ensure accurate placement around the damaged area—not directly into the tendon substance, which can cause collagen damage. The skin is anesthetized with ice or topical spray, and the needle is advanced until the tip is adjacent to the hypoechoic or thickened tendon region. A peppering technique (multiple small volume injections) is often used to distribute growth factors over a larger area. Post-injection, athletes are instructed to rest for 24–48 hours, then begin a progressive loading program under the guidance of a physical therapist. Typical protocols involve 2–3 injections spaced 4–6 weeks apart depending on clinical response.

Rehabilitation After PRP Injection

Rehabilitation is an integral part of PRP treatment. Without appropriate mechanical loading, the growth factors released by PRP may not be effectively directed into functional tissue repair. A phased approach is recommended. Phase 1 (first 1–2 weeks): relative rest, ice, and gentle range-of-motion exercises; avoid heavy loading. Phase 2 (weeks 2–6): isometric strengthening, progressing to eccentric loading as tolerated. For Achilles tendinopathy, this often involves heel-drop eccentric exercises. Phase 3 (weeks 6–12): sport-specific training, plyometrics, and gradual return to full activity. The entire process typically requires 8–16 weeks before return to pre-injury sport, though this varies by injury severity and sport demands. Compliance with rehabilitation is strongly associated with successful outcomes.

Future Directions and Standardization

The future of PRP therapy lies in precision and personalization. Advances in platelet quantification and characterization—such as measuring growth factor concentrations or using platelet microRNAs—may allow clinicians to tailor treatment to specific injuries and patients. Studies are exploring combining PRP with hyaluronic acid, stem cells, or scaffold materials to enhance efficacy. Another promising direction is the use of autologous conditioned plasma (ACP) or other modern preparation systems that yield more consistent leukocyte and platelet profiles. Large, multicenter RCTs with standardized protocols are urgently needed to resolve controversial areas, especially for rotator cuff and Achilles injuries. Additionally, centralized outcome registries tracking PRP formulation, injury type, and rehabilitation compliance would help guide evidence-based practice. For now, clinicians must integrate the best available evidence, patient preferences, and clinical experience. The decision to try PRP should be a shared one between athlete, coach, and medical team, with clear expectations about the timeline and the critical importance of rehabilitation.

Conclusion

Platelet-rich plasma therapy is a promising but imperfect tool for managing tendon injuries in athletes. The strongest evidence supports its use for chronic lateral epicondylitis and patellar tendinopathy, with moderate evidence for Achilles tendinopathy and selected cases of rotator cuff tendinopathy. Outcomes are influenced by PRP preparation methods, injection technique, injury chronicity, and—most importantly—adherence to structured rehabilitation. While PRP is not a guaranteed solution and the literature continues to evolve, it has become a valuable part of the sports medicine armamentarium. As research advances toward standardized protocols and larger clinical trials, the role of PRP will become better defined. Athletes considering PRP should consult with an experienced sports medicine physician who can evaluate the specific injury, discuss current evidence, and design a comprehensive treatment plan that integrates the best available science with the athlete’s unique goals.